Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies
Telomir Pharmaceuticals (NASDAQ:TELO) has announced significant new in vitro data for its lead compound Telomir-1, revealing its ability to inhibit KDM5 family members, adding to its previously known KDM2/KDM6 and DNA methylation activity.
The breakthrough demonstrates Telomir-1's potential as a first-in-class broad-spectrum epigenetic reset therapy. The compound targets both histone demethylases and DNA methylation, key mechanisms in cancer progression and aging. In previous studies, Telomir-1 showed greater activity than chemotherapy and rapamycin in reducing abnormal DNA methylation and reactivating tumor suppressors.
The company is currently advancing IND-enabling studies and GMP scale-up for Telomir-1, with ongoing preclinical evaluations in aggressive cancers and aging models.
Telomir Pharmaceuticals (NASDAQ:TELO) ha annunciato nuovi dati in vitro significativi per il suo composto principale Telomir-1, rivelando la sua capacità di inibire i componenti della famiglia KDM5, aggiungendo a precedenti attività su KDM2/KDM6 e alla metilazione del DNA.
La scoperta evidenzia il potenziale di Telomir-1 come terapia epigenetica di reset ampio e di prima classe. Il composto prende di mira sia le demetilasi degli istoni sia la metilazione del DNA, meccanismi chiave nella progression del cancro e nell'invecchiamento. In studi precedenti, Telomir-1 ha mostrato attività superiore a chemioterapia e rapamicina nel ridurre la metilazione del DNA anomala e nel riattivare i soppressori tumorali.
La società sta attualmente avanzando studi abilitanti IND e la scalatura GMP per Telomir-1, con valutazioni precliniche in tumori aggressivi e modelli di invecchiamento in corso.
Telomir Pharmaceuticals (NASDAQ:TELO) ha anunciado datos in vitro significativos de su compuesto líder Telomir-1, revelando su capacidad para inhibir a los miembros de la familia KDM5, añadiéndose a su actividad previamente conocida en KDM2/KDM6 y en la metilación del ADN.
El avance demuestra el potencial de Telomir-1 como una terapia epigenética de restablecimiento de amplio espectro de primera clase. El compuesto apunta tanto a desmetilasas de histonas como a la metilación del ADN, mecanismos clave en la progresión del cáncer y el envejecimiento. En estudios anteriores, Telomir-1 mostró mayor actividad que la quimioterapia y la rapamicina para reducir la metilación anormal del ADN y reactivar los supresores tumorales.
La empresa está avanzando actualmente con estudios habilitantes de IND y escalado GMP para Telomir-1, con evaluaciones preclínicas en cánceres agresivos y modelos de envejecimiento en curso.
Telomir Pharmaceuticals (NASDAQ:TELO)가 주된 화합물 Telomir-1의 새로운 중요한 in vitro 데이터를 발표했습니다. 이는 KDM5 가족 구성원을 억제하는 능력을 보여주며, 이전에 알려진 KDM2/KDM6 및 DNA 메틸화 활성에 보태어 새로운 정보를 제공합니다.
이 돌파구는 Telomir-1의 가능성을 일류의 광범위한 에피제네틱 리셋 치료제로 제시합니다. 이 화합물은 히스톤 디메틸화효소와 DNA 메틸화를 모두 표적으로 삼아 암 진행과 노화의 주요 메커니즘에 관여합니다. 이전 연구에서 Telomir-1은 정상 DNA 메틸화 감소와 종양 억제 유전자의 재활성화에서 화학요법 및 랩마이신보다 더 큰 활성을 보였습니다.
회사는 현재 Telomir-1에 대한 IND-인증 가능 연구 및 GMP 규모 확장 작업을 진행 중이며, 진행 중인 전임상 평가가 공격적 암 및 노화 모델에서 이루어지고 있습니다.
Telomir Pharmaceuticals (NASDAQ:TELO) a publié des données in vitro significatives pour son composé phare Telomir-1, révélant sa capacité à inhiber les membres de la famille KDM5, s’ajoutant à son activité déjà connue sur KDM2/KDM6 et la méthylation de l’ADN.
Cette avancée démontre le potentiel de Telomir-1 en tant que thérapie épigénétique de réinitialisation à large spectre de première classe. Le composé cible à la fois les déméthylases des histones et la méthylation de l’ADN, des mécanismes clés dans la progression du cancer et le vieillissement. Dans des études antérieures, Telomir-1 a montré une activité supérieure à celle de la chimiothérapie et de la rapamycine pour réduire une méthylation anormale de l’ADN et réactiver les suppresseurs de tumeur.
L’entreprise fait actuellement progresser des études IND-enabled et une montée en échelle GMP pour Telomir-1, avec des évaluations précliniques en cours dans des cancers agressifs et des modèles de vieillissement.
Telomir Pharmaceuticals (NASDAQ:TELO) hat signifikante neue in vitro-Daten für seine Leitverbindung Telomir-1 bekannt gegeben und gezeigt, dass es die KDM5-Familienmitglieder hemmen kann, zusätzlich zu der zuvor bekannten Aktivität gegenüber KDM2/KDM6 und der DNA-Methylierung.
Der Durchbruch demonstriert das Potenzial von Telomir-1 als erstes Breitband-Epigenetik-Neustart-Therapie. Die Verbindung zielt auf sowohl Histon-Demethylasen als auch DNA-Methylierung ab, zentrale Mechanismen in der Krebsprogression und dem Altern. In früheren Studien zeigte Telomir-1 eine größere Aktivität als Chemotherapie und Rapamycin bei der Reduktion abnormer DNA-Methylierung und der Reaktivierung von Tumorsuppressoren.
Das Unternehmen treibt derzeit IND- enabling Studien und GMP-Skalierung für Telomir-1 voran, mit laufenden präklinischen Bewertungen in aggressiven Krebsarten und Alterungsmodellen.
Telomir Pharmaceuticals (NASDAQ:TELO) أعلنت عن بيانات جديدة مهمة في المختبر (in vitro) لمرشحها الرائد Telomir-1، تكشف عن قدرته على تثبيط أعضاء عائلة KDM5، إضافة إلى نشاطه المعهود سابقاً على KDM2/KDM6 وتثبيط ميثلة DNA.
يظهر هذا التطور إمكانات Telomir-1 كـ علاج إعادة ضبط وراثي epitomic شام من الفئة الأولى. يستهدف المركب كلاً من ديمتيلات الهستون وميثلة DNA، وهي آليات رئيسية في تقدم السرطان والشيخوخة. في دراسات سابقة، أظهر Telomir-1 نشاطاً أعلى من العلاج الكيميائي وراباميسين في تقليل ميثلة DNA غير الطبيعية وإعادة تنشيط عوامل كبح الورم.
تواصل الشركة حالياً دراسات تمهيدية قبل تقديم IND وتوسيع GMP لـ Telomir-1، مع تقييمات ما قبل سريرية في سرطانات عدوانية ونماذج الشيخوخة قيد التقدم.
Telomir Pharmaceuticals (NASDAQ:TELO)宣布了其首要化合物 Telomir-1在体外的显著新数据，显示其能够抑制KDM5家族成员，这补充了其先前已知对KDM2/KDM6以及DNA甲基化的活性。
这一突破表明 Telomir-1 有望成为一种 同类第一的广谱表观遗传重置治疗。该化合物同时靶向组蛋白去甲基化酶和DNA甲基化，这是癌症进展和衰老过程中的关键机制。在先前的研究中，Telomir-1 显示的活性超过化疗和雷帕霉素，在减少异常DNA甲基化和重新激活肿瘤抑制基因方面具有优势。
该公司目前正在推进 Telomir-1 的 IND 启用研究以及 GMP 大规模生产准备，同时在侵袭性癌症和衰老模型中进行前临床评估。
- Novel dual mechanism targeting both histone demethylases and DNA methylation pathways
- Demonstrated greater activity than chemotherapy and rapamycin in previous prostate cancer studies
- Potent inhibition of three KDM5 family members while sparing broad acetyltransferases associated with toxicity
- Advancing toward IND submission with ongoing preclinical evaluations
- Still in preclinical stage with no human trial data available
- Complex drug development pathway in challenging therapeutic area
- Multiple mechanism of action could potentially increase risk of side effects
Insights
Telomir-1 shows promising preclinical activity against multiple epigenetic targets involved in cancer and aging, representing a potential breakthrough approach.
Telomir Pharmaceuticals' latest in vitro data reveals that Telomir-1 now demonstrates inhibition of three distinct histone demethylase families (KDM5, KDM2, and KDM6), plus effects on DNA methylation. This is scientifically significant because these epigenetic regulators control critical gene expression patterns that become dysregulated in cancer and aging.
The KDM5 family inhibition is particularly noteworthy as these enzymes erase activating marks from tumor suppressor genes, effectively silencing protective mechanisms against cancer. Meanwhile, KDM2/KDM6 families operate differently by removing repressive marks from genes involved in inflammation and proliferation. By targeting both mechanisms simultaneously, Telomir-1 could potentially restore a healthier balance of gene expression.
What separates Telomir-1 from other epigenetic candidates is its dual-layer approach. Most epigenetic drugs target either histone modifications OR DNA methylation - not both. This compound appears to address both the "switches" (histone demethylases) and the "locks" (DNA methylation) that silence protective genes and activate harmful ones.
That said, these remain preclinical findings. The leap from in vitro potency to in vivo efficacy is substantial, and many promising epigenetic therapies have struggled with selectivity, bioavailability, and toxicity in clinical development. The company is advancing toward IND-enabling studies, but efficacy and safety in humans remain to be established. The unique inhibition profile is scientifically intriguing, but clinical validation will be the true test of Telomir-1's potential.
The expanded mechanistic profile of Telomir-1 represents a significant enhancement to Telomir's value proposition. What makes this announcement noteworthy is the unprecedented breadth of epigenetic targets - now spanning three distinct histone demethylase families plus DNA methylation effects - a combination not seen in other development-stage epigenetic drugs.
For context, epigenetic dysregulation represents a fundamental hallmark of both cancer and aging, making it an attractive but challenging therapeutic frontier. Current epigenetic drugs (like HDAC inhibitors) have shown clinical benefit but are often limited by narrow mechanistic focus and toxicity profiles.
Telomir-1's potential competitive advantage lies in its multi-faceted approach to epigenetic reprogramming. By simultaneously targeting the KDM5 family (which silences tumor suppressors), the KDM2/KDM6 families (involved in inflammation and proliferation), and DNA methylation patterns, the compound theoretically addresses multiple layers of epigenetic dysregulation.
From a development perspective, Telomir is still in preclinical stages with IND-enabling studies ongoing. This places commercialization several years away at minimum, with all the associated development risks. The complexity of Telomir-1's mechanism could be either a strength (unprecedented efficacy) or weakness (potential for off-target effects or toxicity).
These new findings strengthen Telomir's scientific foundation and potential addressable markets across cancer and age-related diseases. However, investors should recognize that the path from promising preclinical data to approved therapy remains long and uncertain, with clinical validation representing the next critical milestone.
New in vitro results show Telomir-1 adds KDM5 family inhibition to its previously reported KDM2/KDM6 and DNA methylation activity, potentially representing a novel frontier in epigenetic therapy where no existing candidates have shown comparable breadth.
MIAMI, FLORIDA / ACCESS Newswire / September 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a preclinical-stage biotechnology company developing therapies that target the root causes of cancer, aging, and age-related diseases, today announced new in vitro pharmacology results demonstrating that Telomir-1 potently inhibits three members of the KDM5 histone demethylase family.
Histone demethylases are upstream gene regulators that cancers exploit to silence tumor suppressors and activate inflammatory programs. Blocking these enzymes has long been viewed as scientifically important but clinically challenging, with KDM5 often described as challenging for development
Why This Matters
Cancer and aging are driven in part by the silencing of protective genes that regulate cell growth, repair, and survival. When these genes are inactive, cells lose critical defenses, enabling tumors to expand and age-related decline to progress.
This silencing occurs through two major mechanisms:
Histone demethylases (the switches):
Members of the KDM5 family are frequently overactive in cancers. Their role is to erase the "on" marks from tumor suppressor genes. When members of the KDM5 family do this, critical genes that normally stop uncontrolled cell growth, repair damage, or trigger cell death are effectively turned off - leaving cancer cells free to divide and accumulate mutations. KDM5 family members are mainly involved in cell cycle progression, stemness, and cancer drug resistance.
Members of the KDM2 and KDM6 families work differently. They remove "off" marks from genes that drive inflammation and cell proliferation. While KDM2 family members are mainly involved in gene repression or silencing, often linked with chromatin remodeling and some anti-cancer effects, the KDM6 family members are known for promoting gene activation which is tightly associated with developmental processes, inflammatory responses, and cancer subtype determination
Together, these enzymes push the balance in the wrong direction: shutting down the genes that protect cells while activating the ones that promote disease.
DNA methylation (the locks):
After histone changes switch genes off, a second layer of control reinforces the silence through DNA methylation.
This process involves adding small chemical tags (methyl groups) directly onto the DNA near gene promoters.
When these tags accumulate, the gene is no longer accessible to the cell's transcription machinery - in effect, the gene is shut down.
Importantly, these methylation patterns are copied every time a cell divides, which means the silence is passed on from one generation of cells to the next.
In cancer, this permanently disables tumor suppressor genes like CDKN2A and STAT1, removing critical brakes on cell growth and immune defense.
In aging, widespread changes in DNA methylation contribute to epigenetic drift - the gradual loss of normal gene regulation that underlies tissue decline and age-related disease.
Telomir-1 has now demonstrated the potential to reset both layers of control:
In the new in vitro studies, Telomir-1 potently inhibited three members of the KDM5 family, blocking the silencing of protective genes and preventing the activation of harmful inflammatory pathways.
Telomir-1 previously demonstrated activity across other families of histone demethylases, including UTX (KDM6A), JMJD3 (KDM6B), FBXL10 (KDM2B), and FBXL11 (KDM2A). These enzymes are associated with cancer progression, stemness, immune evasion, and age-related decline. Telomir-1 was also shown to spare broad acetyltransferases such as GCN5L2, which are associated with systemic toxicity when inhibited.
In other previously reported in vivo prostate cancer studies, Telomir-1 reduced abnormal DNA methylation and reactivated tumor suppressors such as CDKN2A and STAT1, with greater activity than chemotherapy and rapamycin.
By acting at both the histone and DNA levels, Telomir-1 is emerging as a first-in-class, broad-spectrum epigenetic reset therapy with the potential to restore fundamental cellular defenses relevant to cancer and aging.
"This is a breakthrough," said Erez Aminov, Chief Executive Officer of Telomir. "Telomir-1 is demonstrating the potential to create an entirely new class of treatments aimed at the root biology of cancer, aging, and other serious diseases."
"Showing that Telomir-1 can potently inhibit several family members of three types of histone demethylases, known to present drug discovery challenges such as selective targeting, cellular permeability, and context-dependent effects, is highly significant," added Dr. Itzchak Angel, Chief Scientific Advisor at Telomir. "It suggests a new path for tackling how cancers silence protective genes and how aging erodes cellular defenses."
Taken together, Telomir-1 demonstrates an unusually broad impact across both DNA methylation and histone demethylation pathways - the fundamental axes of epigenetic control.
Advancing Toward the Clinic
Telomir continues to advance IND-enabling studies and GMP scale-up for Telomir-1, with additional preclinical evaluations ongoing across aggressive cancers and models of aging. The Company expects these findings to support its upcoming IND submission.
About Telomir Pharmaceuticals
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a preclinical-stage biotechnology company developing small-molecule therapies that target the root causes of cancer, aging, and age-related diseases by resetting dysregulated epigenetic programs. The Company's lead candidate, Telomir-1, is being advanced across oncology and longevity indications based on its differentiated ability to restore tumor suppressors, block undruggable enzymes, and reprogram gene control. For more information, visit www.telomirpharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release, statements of Telomir's management or advisors related thereto, and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.
Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which are on file with the SEC and available at www.sec.gov. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact Information
Helga Moya
info@telomirpharma.com
(786) 396-6723
SOURCE: Telomir Pharmaceuticals, Inc
View the original press release on ACCESS Newswire
FAQ
What is Telomir-1's mechanism of action in cancer treatment?
How does Telomir-1 differ from existing cancer therapies?
What stage of development is TELO's Telomir-1 currently in?
How effective was Telomir-1 in preclinical studies?
What diseases could Telomir-1 potentially treat?
